• Small Molecules
      • Discovery
    • Biologics
    • Other Drug Modalities
    • SynVent Integrated Drug Discovery
      • SynVent Integrated Drug Discovery

        SynVent is Syngene’s platform for fully integrated therapeutic discovery and development across large and small molecules. 

    • Industries
    • Emerging Biopharma
      • Emerging Biopharma

        Emerging biopharma work at the forefront of science, often venturing into disease areas where little or no real-world data exists to work with or regulatory frameworks to work within.

    • Dedicated Centers
      • Dedicated Centers

        Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support their  R&D  goals

    • Center for Advanced Protein Studies (CAPS)
      • Center for Advanced Protein Studies (CAPS)

        Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.

  • Careers

Antibody Drug Conjugates

Combining the targeting capabilities of antibodies and the cell-killing ability of cytotoxic drugs, antibody drug conjugates (ADCs) are an important and powerful therapeutic modality. Due to their molecular complexity and potential toxicity accompanied by a rapidly evolving technological landscape, ADC research demands a significant shift from traditional large molecule discovery and development paradigms. What sets apart Syngene from most global CROs is a highly integrated ‘one-stop-shop’ approach to ADC research, underpinned by strong conceptual frameworks, experimental design and expertise in troubleshooting. Augmented by expertise in target selection, antibody discovery, bioanalysis and cGMP manufacturing, Syngene can drive successful outcomes for our ADC clients.

Our ADC services

  • Linker-payload optimization, synthesis and scale-up
  • Antibody engineering and production
  • Conjugation optimization and scale-up
  • ADC purification and analytical characterization
  • Efficacy evaluation (in vitro and in vivo)
  • Pharmacokinetics and tox evaluation

Our track record

  • Development of a novel self-immolative linker-payload system (patent filed by client) from concept through preclinical proof
  • Employing a first in category antibody format to drive a candidate through to IND filing
  • Improvement of solubility and efflux properties of a class of payloads though rational design
  • Total synthesis of various novel payload analogs in several major categories (duocarmycins, tubulysins and PBD dimers)

Your browser does not support this function.

To download, Please share your details

This Website uses Cookies

We use cookies to improve your experience on our site and show you information relevant to your requirements.

To find out more, read our Privacy Policy and Cookies Policy.

To view or email, Please share your details view

To download, Please share your details